nature portfolio

Corresponding author(s):	Jeremy Keown and Jonathan Grimes	
Last updated by author(s):	Jun 20, 2023	

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and code
Policy information about <u>availability of computer code</u>
Data collection GDA

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

DIALS v1, xia2.multiplex v1, coot v0.98, Phenix v1.19-1.21, chimeraX v1.4-1.6, PyMOL 2.4.1, CRANK 1.5, trRosetta v1, AlphaFold 2 (as Collab

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data are available from the corresponding authors and/or included in the paper or Supplementary information. Crystallographic data generated in this study have been deposited in the PDB including accession codes 8BBT [http://doi.org/10.2210/pdb8BBT/pdb] (archival sample), 8BC5 [http://doi.org/10.2210/pdb8BC5/pdb] (selenomethionine data), 8BCK [http://doi.org/10.2210/pdb8BCK/pdb] (recombinant data), and 8BCL [http://doi.org/10.2210/pdb8BCL/pdb] (recombinant data), 8BCK [http://doi.org/10.2210/pdb8BCL/pdb] (recombinant data)

		provided with this pape H5/pdb] are available ir	er. Data generated in previous studies (PDB ID: 3JVB [http://doi.org/10.2210/pdb3JVB/pdb] and PDB ID: n the PDB.		
uman rese	arch parti	cipants			
		•	arch participants and Sex and Gender in Research.		
		,			
Reporting on sex and gender N/A					
Population characteristics N/A		N/A			
ecruitment		N/A			
thics oversight		N/A			
e that full informa	ation on the appr	oval of the study protoc	col must also be provided in the manuscript.		
eld-spe	ecific re	porting			
		·	research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences	E	ehavioural & social so	ciences Ecological, evolutionary & environmental sciences		
reference copy of t	the document with	all sections, see <u>nature.con</u>	m/documents/nr-reporting-summary-flat.pdf		
fo scier	nces sti	udy desigr	\cap		
			e disclosure is negative.		
ample size			sample size was not pre-calculated. Instead data was collected until strong signal above the noise was This sample size was deemed sufficient as it gave enough signal to solve and determine the structures.		
	For SDS-PAGE	experiments, duplicate s	sample were run and showed similar results.		
ata exclusions	Data was exclu	as excluded from crystals with weak diffraction.			
eplication		DS-PAGE experiments, duplicate sample were run and showed similar results. Recombinant crystal production was carried out at least times and diffraction was similar for both preparations.			
andomization		omization of samples is not appropriate for these experiments as we needed to know which samples were being collected. During ssing of the X-ray crystallography data a random 5% of reflections were not used in refinement to instead be used in validation.			
linding	Blinding was no	nding was not appropriate as decisions had to be made on the correct type of analysis for the different samples.			
eportin	g for si	pecific ma	nterials, systems and methods		
require informati	on from authors	about some types of ma	aterials, experimental systems and methods used in many studies. Here, indicate whether each material,		
tem or method list	ted is relevant to	your study. It you are n	ot sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & experimental systems		ystems 1	Methods		
a Involved in the study		n	n/a Involved in the study		
Antibodies			ChIP-sea		

Materials & experimental systems			Methods		
n/a	Involved in the study	n/a	Involved in the study		
\boxtimes	Antibodies	\boxtimes	ChIP-seq		
	Eukaryotic cell lines	\boxtimes	Flow cytometry		
\times	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging		
\times	Animals and other organisms				
\times	Clinical data				
\boxtimes	Dual use research of concern				

Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>

Cell line source(s) SF9 cells were sourced from the Division of Structural Biology cell bank at the University of Oxford.

Authentication Authentication was not performed for this study.

Mycoplasma contamination Mycoplasma contamination was not performed for this study

Commonly misidentified lines (See <u>ICLAC</u> register)

No commonly misidentified cell lines were used in this study.